Canada Myocardial Infarction Market to reach $211.0 million by 2035

Canada myocardial infarction market was valued at approximately $138.4 million in 2025 and is projected to reach around $211.0 million by 2035, expanding at a CAGR of 4.4% during 2026–2035. Market growth is driven by the increasing prevalence of cardiovascular diseases and rising adoption of advanced interventional and diagnostic technologies. According to the World Health Organization, cardiovascular diseases account for nearly 19.8 million deaths annually worldwide, representing about 32% of total global mortality. This growing burden is significantly increasing the demand for early diagnosis and effective treatment of Myocardial Infarction through ECG, biomarker testing, imaging, and advanced revascularization procedures across hospitals and surgical centers in Canada.

Browse the full report description of “Canada Myocardial Infarction Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatment Interventional Procedures, Adjunct & Supportive Care), Coronary Artery Bypass Grafting (CABG), Advanced/Adjunct Therapies), By Medical Device Type (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, and Others), By End-User (Hospitals, Specialty Centres, ASCs), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/canada-myocardial-infarction-market

The key players in the Canada myocardial infarction market include top companies such as Cardinal Health, Pfizer Inc., AstraZeneca, Abbott Laboratories, and Medtronic, among others. The market is witnessing steady growth due to the increasing use of advanced treatment approaches such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and adjunctive therapies. Additionally, improvements in diagnostic accuracy through imaging and biomarker testing are enabling faster clinical decision-making and better patient outcomes.

Recent Developments

• In January 2026, Novo Nordisk announced that Health Canada has approved RYBELSUS (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.

• In November 2024, Canada approved Novo Nordisk’s obesity drug Wegovy to reduce the risk of non-fatal heart attack (myocardial infarction) in adults with established cardiovascular disease. This marks the first treatment in the country targeting both obesity and related heart risks.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
• By Treatment Type
• Medical Device Type
• By End User

Competitive Landscape: Cardinal Health, Pfizer, AstraZeneca, Abbott, and Medtronic, among others.

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Canada Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Adjunct & Supportive Care

By Medical Device Type

• Left Ventricular Assist Device
• Pacemaker
• Catheters
• Implantable Cardioverter Defibrillator
• Others

By End-User

• Public Hospitals
• Private Hospitals
• Cardiac Specialty Centers
• Ambulatory Surgical Centers

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/canada-myocardial-infarction-market